• General multiple sclerosis (MS)
  • MS - Dimethyl fumarate
  • MS - Natalizumab
    • The areas of research currently being considered to support studies related to natalizumab in multiple sclerosis can be found below.

      In scope:  

      1. Effectiveness as assessed by clinical, MRI, biomarker endpoints as well as PROs, specifically:
        • Efficacy after switching from newer DMTs
        • Natalizumab discontinuation strategies with DMTs
      2. MRI or fluid biomarkers identifying patient populations that would benefit most from earlier treatment with natalizumab

      Out of scope:

      1. Studies describing the prevalence of the anti-JCV antibody and/or the numeric value of the anti-JCV antibody index in general
      2. Work on additional biomarkers for PML risk mitigation
      3. Single site studies on clinical efficacy and/or electrophysiological measures or OCT
         

      Of note: Study designs for research objectives that have been well-researched in the past need to be powered to derive statistically meaningful conclusions and provide new scientific observations.

      Research support is awarded on a highly competitive basis, and submission of research proposals in these areas of interest does not guarantee that support will be awarded.

  • MS - Peginterferon beta-1a
  • MS - Prolonged-release fampridine